Roche Alzheimer’s Push May Gain From Obama Brain-Mapping Plan

By Shannon Pettypiece & Michelle Fay Cortez Roche AG and Eli Lilly & Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, ...

Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?

By John LaMattina More than a decade ago, Mercklaunched Vioxx (rofecoxib),  one of the first of a new class of pain relievers known as COX-2 inhibitors. These compounds, by virtue ...

Will Sequester End Drug Approvals? Not Unless White House Wants it to

By Scott Gottlieb As sequester looms likely, there’s focus on what it means for Federal agencies, including the Food and Drug Administration (FDA). Last time FDA had its budget clipped ...

Takeda Faces First Trial Over Actos Diabetes Drug in L.A.

By Jef Feeley & Margaret Cronin Fisk Takeda Pharmaceutical Co., Asia’s biggest drugmaker, is facing its first trial of lawsuits alleging that its Actos diabetes drug caused ...

Amgen’s Future Is Brighter Than You Might Think

By Maxx Chatsko When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping overAmgen (NASDAQ: AMGN  ) . You don’t have ...

Medical device tax petition for repeal brings in 9,000+ signers

By Nancy Ryerson An online petition calling to repeal the medical device tax has collected more than 9,000 signatures from medical device employees around the country. Created by medical ...

BIOTRONIK’s Ilesto 7 Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Cleared in EU

By GENE OSTROVSKY  BIOTRONIK’s Ilesto 7 ICD’s and CRT-D’s that feature ProMRI technology received CE Mark clearance from European authorities. The devices are meant to be MRI ...

USPSTF Reviews Therapies for Open-Angle Glaucoma

Medical, laser, and surgical treatments reduce intraocular pressure; comparative efficacy unclear By HealthDay News  The U.S. Preventive Services Task Force has reviewed the comparative ...

Sanofi says FDA to review diabetes drug lixisenatide

(Reuters) – French drugmaker Sanofi said on Tuesday that its experimental diabetes drug lixisenatide has been accepted for review by the U.S. Food and Drug Administration. The ...

Drug Makers, in Shift, Join Fight Against Doping

By KATIE THOMAS The blood-enhancing drug EPO has improved the lives of millions of anemia patients, but  Lance Armstrong and other top cyclists have turned the medicine into ...

CMV Retinitis Drug Recalled

By John Gever One lot of cidofovir for intravenous infusion (Vistide), used to treat an opportunistic eye infection in AIDS patients, has been recalled because of particulate matter ...

Vasella’s $78 Million Novartis Payout Boosts ‘Fat-Cat’ Crackdown

By Simeon Bennett & Patrick Winters Novartis AG’s 72 million Swiss-franc ($78 million) payout to prevent outgoing chairman Daniel Vasella from working for a rival undermines ...
Page 30 of 53« First...1020...2829303132...4050...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS